The DOI matches its Crossref record; 37 of the 37 references it cites were found in a registry or an index.
Prevalence of Optimal Treatment Regimens in Patients With Apparent Treatment-Resistant Hypertension Based on Office Blood Pressure in a Community-Based Practice Network
Open accessAbstract
Hypertensive patients with clinical blood pressure (BP) uncontrolled on ≥3 antihypertensive medications (ie, apparent treatment-resistant hypertension [aTRH]) comprise ≈28% to 30% of all uncontrolled patients in the United States. However, the proportion receiving these medications in optimal doses is unknown; aTRH is used because treatment adherence and measurement artifacts were not available in electronic record data from our >200 community-based clinics Outpatient Quality Improvement Network. This study sought to define the proportion of uncontrolled hypertensives with aTRH on optimal regimens and clinical factors associated with optimal therapy. During 2007–2010, 468 877 hypertensive patients met inclusion criteria. BP <140/<90 mm Hg defined control. Multivariable logistic regression was used to assess variables independently associated with optimal therapy (prescription of diuretic and ≥2 other BP medications at ≥50% of maximum recommended hypertension doses). Among 468 877 hypertensives, 147 635 (31.5%) were uncontrolled; among uncontrolled hypertensives, 44 684 were prescribed ≥3 BP medications (30.3%), of whom 22 189 (15.0%) were prescribed optimal therapy. Clinical factors independently associated with optimal BP therapy included black race (odds ratio, 1.40 [95% confidence interval, 1.32–1.49]), chronic kidney disease (1.31 [1.25–1.38]), diabetes mellitus (1.30 [1.24–1.37]), and coronary heart disease risk equivalent status (1.29 [1.14–1.46]). Clinicians more often prescribe optimal therapy for aTRH when cardiovascular risk is greater and treatment goals lower. Approximately 1 in 7 of all uncontrolled hypertensives and 1 in 2 with uncontrolled aTRH are prescribed ≥3 BP medications in optimal regimens. Prescribing more optimal pharmacotherapy for uncontrolled hypertensives including aTRH, confirmed with out-of-office BP, could improve hypertension control.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Among treated adults with hypertension, prevalent aTRH occurs in ≈12% to 15% of population-based13–16 and 15% to 18% of clinic-based reports.17–20”
From Resistant Hypertension: Detection, Evaluation, and Management: A Scientific Statement From the American Heart Association (2018) · cites this paper as [20]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Toprak, Ö., Kurt, H., Sarı, Y., Şarkış, C., Us, H., & Kırık, A. (2017) · Kidney & Blood Pressure Research · doi:10.1159/000468530 · Cited by 29,772
Chobanian, A. V. (2003) · JAMA · doi:10.1001/jama.289.19.2560 · Cited by 25,386
Chobanian, A. V., Bakris, G. L., Black, H. R., Cushman, W. C., Green, L. A., Izzo, J. L., Jones, D. W., Materson, B. J., Oparil, S., Wright, J. T., et al. (2003) · Hypertension · doi:10.1161/01.hyp.0000107251.49515.c2 · Cited by 13,271
Ahmed, A., Jorna, T., & Bhandari, S. (2016) · The Nephron journals/Nephron journals · doi:10.1159/000447068 · Cited by 11,782
Levey, A. S., Coresh, J., Greene, T., Stevens, L. A., Zhang, Y., Hendriksen, S. M., Kusek, J. W., & Lente, F. V. (2006) · Annals of Internal Medicine · doi:10.7326/0003-4819-145-4-200608150-00004 · Cited by 5,726
Differential Diagnosis of Glomerular Disease: A Systematic and Inclusive Approach
Hebert, L. A., Parikh, S. M., Prosek, J. M., Nádasdy, T., & Rovin, B. H. (2013) · American Journal of Nephrology · doi:10.1159/000354390 · Cited by 4,392
Effects of intensive blood-pressure control in type 2 diabetes mellitus
(2010) · New England Journal of Medicine · doi:10.1056/nejmoa1001286 · Cited by 3,598
Resistant Hypertension: Diagnosis, Evaluation, and Treatment
Calhoun, D. A., Jones, D. W., Textor, S. C., Goff, D. C., Murphy, T. P., Toto, R. D., White, A. J., Cushman, W. C., White, W. B., Sica, D. A., et al. (2008) · Circulation · doi:10.1161/circulationaha.108.189141 · Cited by 2,240
Self-citationUS trends in prevalence, awareness, treatment, and control of hypertension, 1988–2008
Egan, B. M. (2010) · JAMA · doi:10.1001/jama.2010.650 · Cited by 2,197
Self-citationThe J-Curve Phenomenon in Hypertension
Kang, Y., & Wang, J. (2016) · Pulse · doi:10.1159/000446922 · Cited by 1,551
Cited by
Sorted by citations
Items 101–158 of 158
Managing Treatment-Resistant Patients
Schmieder, R. E. (2015) · High Blood Pressure & Cardiovascular Prevention · doi:10.1007/s40292-015-0098-z · Cited by 3
Comment on Optimal Treatment for Resistant Hypertension: The Missing Data on Pulse Wave Velocity
Elias, M. F., & Sullivan, K. (2014) · Hypertension · doi:10.1161/hypertensionaha.113.02742 · Cited by 3
Waeber, B., & Feihl, F. (2013) · Hypertension · doi:10.1161/hypertensionaha.113.01800 · Cited by 3
Resistant hypertension: focus on vascular lesions
Сергеевна, Л. М., Хаишева, Л. А., & Shlyk, S. V. (2020) · South Russian Journal of Therapeutic Practice · doi:10.21886/2712-8156-2020-1-3-16-26 · Cited by 2
Holliday, M., Burnett, A., Leavitt, M., Knapke, J. M., Hargraves, D., & Pallerla, H. (2022) · Journal of Continuing Education in the Health Professions · doi:10.1097/ceh.0000000000000468 · Cited by 2
Options for patients with out-of-control blood pressure: after all avenues have been exhausted
Zeng, W., & Tomlinson, B. (2024) · Expert Review of Cardiovascular Therapy · doi:10.1080/14779072.2024.2401875 · Cited by 2
American Society of Hypertension Scientific Statements Addressing Resistant Hypertension
Turner, J. R., & Lee, J. (2015) · Journal of Clinical Hypertension · doi:10.1111/jch.12617 · Cited by 3
Mineralocorticoid receptor antagonism as an add-on treatment for resistant hypertension
Rossi, G. P., & Maiolino, G. (2014) · Hypertension Research · doi:10.1038/hr.2014.139 · Cited by 2
Henine, N., Kichou, B., Kichou, L., Benbouabdellah, M., Boubchir, M. A., Madiou, A., Hammouche, A., & Saheb, B. (2016) · Annales de Cardiologie et d Angéiologie · doi:10.1016/j.ancard.2016.04.003 · Cited by 2
Depression and race affect hospitalization costs of heart failure patients
Husaini, B. A., Levine, R. S., Novotny, M. L., Cain, V. A., Sampson, U. K. A., & Moonis, M. (2015) · Family Medicine and Community Health · doi:10.15212/fmch.2015.0118 · Cited by 2
Prevalence of coronary risk factors in load transport drivers
Braga, B. B., Ferreira, F. G., Reis, H. H. T., & Marins, J. C. B. (2022) · Revista Brasileira de Medicina do Trabalho · doi:10.47626/1679-4435-2022-695 · Cited by 2
When the Going Gets Tough, the Tough Get Going
de Ledesma, A. R. (2015) · EMJ Cardiology · doi:10.33590/emjcardiol/10313301 · Cited by 2
Roger, V. L. (2014) · Circulation · doi:10.1161/circulationaha.114.008390 · Cited by 2
Global Clinical Consequences of Poor Adherence
Perreault, S. (2018) · Updates in hypertension and cardiovascular protection · doi:10.1007/978-3-319-76593-8_22 · Cited by 1
Azizi, M., Lorthioir, A., & Amar, L. (2023) · Elsevier eBooks · doi:10.1016/b978-0-323-88369-6.00047-5 · Cited by 2
Champigny, J., & Nagge, J. J. (2024) · Canadian Pharmacists Journal / Revue des Pharmaciens du Canada · doi:10.1177/17151635241281511 · Cited by 1
Li, Y., Lan, C., Wang, Y., Lei, H., Lu, C., & Liu, Y. (2026) · BMC Public Health · doi:10.1186/s12889-026-27373-6 · Cited by 1
Definitions of Resistant Hypertension and Epidemiology of Resistant Hypertension
Ferro, C. J. (2017) · Springer eBooks · doi:10.1007/978-3-319-56827-0_1 · Cited by 1
Doran, J. A., & Bisognano, J. D. (2018) · Springer eBooks · doi:10.1007/978-3-319-89725-7_15 · Cited by 1
Bobrie, G., Amar, L., Faucon, A., Madjalian, A.-M., & Azizi, M. (2017) · Elsevier eBooks · doi:10.1016/b978-0-323-42973-3.00043-3 · Cited by 1
Choi, S. I., Kim, S. K., Park, S., Kim, J. H., Ihm, S., Kim, G.-I., Kim, W. S., Pyun, W. B., Kim, Y., & Shin, J. (2016) · Clinical Hypertension · doi:10.1186/s40885-016-0048-7
Cost-Utility of an Objective Biochemical Measure to Improve Adherence to Antihypertensive Treatment
Egan, B. M., & Rudisill, C. (2018) · Hypertension · doi:10.1161/hypertensionaha.118.11301 · Cited by 1
Self-citationManolis, A. J. (2020) · Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature · doi:10.3410/f.734299250.793571584 · Cited by 1
Difficult-to-Control or Resistant Hypertension?
Ruilope, L. M. (2013) · Current Cardiovascular Risk Reports · doi:10.1007/s12170-013-0359-0
Egan, B. M., Zhao, Y., Li, J., Brzezinski, W. A., Todoran, T. M., Brook, R. D., & Calhoun, D. A. (2014) · Hypertension · doi:10.1161/hypertensionaha.113.02847
Self-citationLuft, F. C. (2015) · Der Internist · doi:10.1007/s00108-014-3568-9
Dampf ablassen beim resistenten Hochdruck
rb, & bs (2013) · CME · doi:10.1007/s11298-013-0953-y
Interventionelle Verfahren bei therapieresistenter Hypertonie
Tölle, M. (2016) · CardioVasc · doi:10.1007/s15027-016-0823-0
Руденко, Ю. В. (2016) · ScienceRise Medical Science · doi:10.15587/2519-4798.2016.83696
Endocrine Hypertension and Chronic Kidney Disease
Koch, C. A., Pamporaki, C., & Kantorovich, V. (2014) · Springer eBooks · doi:10.1007/978-1-4939-1982-6_16 · Cited by 1
Bhatt, H., Siddiqui, M., Judd, E. K., Oparil, S., & Calhoun, D. A. (2016)
Self-citationLehnig, L.-Y. (2017) · eDiss (Georg-August-Universität Göttingen) · doi:10.53846/goediss-6162
HTA essentielle résistante : place de la spironolactone
Lorthioir, A., Belmihoub, I., Fouassier, D., Azizi, M., & Amar, L. (2019) · La Presse Médicale · doi:10.1016/j.lpm.2019.07.027
Assessment and treatment of resistant hypertension
Plumb, R. D., & Girvin, B. (2020) · Prescriber · doi:10.1002/psb.1829
Hassan, K., Alqahtani, A. D., Alotaibi, M. W., Alahmari, A. A., Alanazi, S. J., Alhussain, G. O., Alnahdi, M. A., Alharbi, F. A., Alshehri, A. A., Aloraini, Z., et al. (2020) · International Journal of Community Medicine and Public Health · doi:10.18203/2394-6040.ijcmph20204419
Device-Based Therapies for Resistant Hypertension: Implications for the Perioperative Clinician
Nuñez-Gil, I. J., Travieso-González, A., Říha, H., & Ramakrishna, H. (2021) · Journal of Cardiothoracic and Vascular Anesthesia · doi:10.1053/j.jvca.2021.10.033
Calhoun, D. A. (2016) · Hypertension Journal · doi:10.5005/jp-journals-10043-0048
Self-citationHipertensão pseudorresistente causada por inadequação do regime terapêutico
Nascimento, V. B., da Silva, R. Z., de Carvalho, J. F., Leopardi-Gonçalves, M. D. G., de Oliveira‐Filho, A. D., & Neves, S. J. F. (2022) · Research Society and Development · doi:10.33448/rsd-v11i9.32004
Causes, Evaluation, and Treatment of Secondary and Resistant Hypertension
Hundemer, G. L. (2022) · Nephrology Self-Assessment Program · doi:10.1681/nsap.00082022
Chronic Kidney Disease and Hypertension
Braam, B. G. (2022) · Wiley eBooks · doi:10.1002/9781119105954.ch35
Владимировна, А. А., Ощепкова, Е. В., Orlovsky, А. A., & Chazova, I. E. (2022) · Systemic Hypertension · doi:10.38109/2075-082x-2022-2-39-46
Hypertension Care: It’s Time to Act
McEvoy, L. (2015) · EMJ Cardiology · doi:10.33590/emjcardiol/10310492
Pulido, M., & Melín, P. (2023) · Studies in computational intelligence · doi:10.1007/978-3-031-22042-5_5
SHARIPOVA, K. Y., Abdulloev, F. N., Гуломович, С. Р., RAKHIMOV, D. D., & NEGMATOV, G. M. (2022) · Avicenna Bulletin · doi:10.25005/2074-0581-2022-24-4-442-451
Hipertensión arterial resistente
Martínez, W. A. R., Mejía, A. F., & Cometa, L. A. V. (2023) · Interdisciplinary Journal of Epidemiology and Public Health · doi:10.18041/2665-427x/ijeph.2.9855
Larina, V. N., Алексеевна, В. Е., Fedorova, E. V., Mikhaylusova, M. P., Saino, O. V., & Mironova, T. N. (2023) · Cardiosomatics · doi:10.17816/cs567844
Lifestyle Management of Refractory Hypertension
李, 成. (2024) · Advances in Clinical Medicine · doi:10.12677/acm.2024.141103
Azizi, M. (2024) · Bulletin de l Académie Nationale de Médecine · doi:10.1016/j.banm.2023.10.005
Device's design and clinical perspectives for resistant hypertension therapy
Jami, O., Allam, O. E., Mohammed, Z., Soulaymane, I., Ilhaam, B. S., Tijani, Y., & Ettahir, A. (2024) · International Journal of Cardiology Cardiovascular Risk and Prevention · doi:10.1016/j.ijcrp.2024.200240
Arana-Morales, G., & Medina-Palomino, F. (2024) · Revista Colombiana de Cardiología · doi:10.24875/rccar.23000004 · Cited by 1
Arana-Morales, G., & Medina-Palomino, F. (2024) · Revista Colombiana de Cardiología (English Edition) · doi:10.24875/rccare.m23000079
Foy, A. (2024) · Trends in Cardiovascular Medicine · doi:10.1016/j.tcm.2024.09.003
Sarfo, F. S., Opare‐Addo, P. A., Agbenorku, M., Obese, V., Adamu, S., Gyamfi, R. A., Akassi, J., Ababio, H., Ampofo, M., Mensah, N. A., et al. (2025) · Equity Neuroscience · doi:10.1016/j.neuros.2025.100013
Aggarwal, A., JAİN, S., Avasthi, R., Sharma, R., & Chawla, D. (2026) · Annals of the National Academy of Medical Sciences (India) · doi:10.25259/anams_127_2024
Observance des traitements antihypertenseurs : méthodologie et aspect clinique
Hamdidouche, I. (2017) · theses.fr (ABES) · doi:10.70675/a6951b2bzc6ddz44d6zb091z1ca3a9e425e1
Hypertension artérielle résistante et maladie rénale chronique : déterminants et risques associés
Kaboré, J. (2016) · theses.fr (ABES) · doi:10.70675/28f5ed83z9110z4f85z8b0fz6ea4e8d0aaae
Селезнев, С. В., Shchulkin, A. V., Mylnikov, P. Y., & Yаkushin, S. S. (2026) · Arterial’naya Gipertenziya (Arterial Hypertension) · doi:10.18705/1607-419x-2026-2526
Abougalambou, S., Abougalambou, A. S., & Hamouda, M. A. (2026) · International Journal of Clinical Medical Research · doi:10.61466/ijcmr4050003
Metadata
- Authors
- Egan, B. M., Zhao, Y., Li, J., Brzezinski, W. A., Todoran, T. M., Brook, R. D., & Calhoun, D. A.
- Affiliations
- Medical University of South Carolina (US)
- Venue
- Hypertension
- Published
- 2013-10
- Volume
- 62
- Issue
- 4
- Pages
- 691-697
- ISSN
- 0194-911X (ISSN-L)
- 1524-4563
- PMC
- PMC4066303
- OpenAlex
- W2142011051
- Cited by
- 158
- References
- 37
- Citations by year
- 2026: 4 · 2025: 1 · 2024: 13 · 2023: 16 · 2022: 12 · 2021: 6 · 2020: 10 · 2019: 8 · 2018: 12 · 2017: 14 · 2016: 21 · 2015: 16 · 2014: 22 · 2013: 3
- FWCI
- 14.04
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- Hypertension (publishedVersion)
- PubMed (publishedVersion)
- PubMed Central (acceptedVersion)
- Funders
- National Institutes of Health
- Centers for Disease Control and Prevention
- National Heart, Lung, and Blood Institute (R34HL105880, R01HL091841, HL091841, HL105880)
- National Institute of Neurological Disorders and Stroke (NS058728, U01NS058728)
- Topics
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Blood Pressure and Hypertension Studies
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Hormonal Regulation and Hypertension
- Health Sciences › Medicine › Public Health, Environmental and Occupational Health › Clinical practice guidelines implementation
- Keywords
- apparent treatment-resistant hypertension, uncontrolled hypertension, office blood pressure, diuretics, chronic kidney disease, diabetes mellitus, coronary heart disease risk, racial disparities, hypertension control, community clinics
- MeSH terms
- Aged, Antihypertensive Agents, Black or African American, Blood Pressure, Blood Pressure Determination, Community Health Services, Female, Humans, Hypertension, Male, Middle Aged, Risk Factors, United States, Prevalence, Treatment Failure, Medication Adherence
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
